Basic ®broblast growth factor (bFGF or FGF-2) is produced by nearly all melanomas in vitro and in vivo but not by normal melanocytes, which require exogenous bFGF for growth. In this study, we transduced normal human melanocytes to overexpress two forms of bFGF: (bFGF-Long and bFGF-Short) using replication-de®cient adenovirus 5 vectors. bFGF-Long induced the 17.8, 22.5, 23.1 and 24.2 kDa forms of bFGF, whereas bFGF-Short induced only the 17.8 kDa mature form. Growth of cultured melanocytes transduced with either vector was similar to that of nevus and melanoma cells and was independent of exogenous bFGF and of insulin/insulinlike growth factor 1, and cyclic AMP enhancers, requiring only phorbol ester as an exogenous mitogen. Like primary melanoma cells, transduced normal melanocytes grew anchorage independently in soft agar. When injected into the dermis of human skin grafted to mice, bFGF-transduced melanocytes proliferated for at least 20 days, whereas cells from control cultures showed poor survival and no proliferation. These results demonstrate that bFGF upregulation is a critical component in melanoma progression.
Introduction
Basic ®broblast growth factor (bFGF or FGF-2) is a ubiquitous cellular mitogen that is not readily secreted due to the lack of a signal peptide sequence . Expression of bFGF is upregulated in many human tumors including melanoma. Whereas normal human melanocytes do not express bFGF (Reed et al., 1994; Scott et al., 1991) , some nevi express it (Ahmed et al., 1997; Mancianti et al., 1993; Ueda et al., 1994) and virtually all melanomas produce bFGF, with expression levels increasing during tumor progression (al-Alousi et al., 1996a,b; Albino et al., 1991) . An autocrine growth stimulatory role for bFGF in melanoma has been clearly established through inhibition of bFGF activity by intracellular injection of blocking antibodies (Halaban et al., 1988) or by suppression of synthesis with antisense oligodeoxynucleotides (Becker et al., 1989) . Inhibition of expression of the FGF receptor 1, which is found on the majority of all melanomas, by antisense oligodeoxynucleotides also inhibits proliferation in vitro (Becker et al., 1992) and in vivo (Wang and Becker, 1997) . The presence of dominant negative receptors (Yayon et al., 1997) and the use of aromatic anionic compounds such as Suramin that sequester bFGF (Davol et al., 1995) have further delineated the autocrine role of bFGF in melanoma progression. Little is known about how bFGF contributes to melanoma development and progression except that its expression is regulated by the HoxB7 homeobox gene (Care et al., 1996) . bFGF is mitogenic not only for melanocytes but also for ®broblasts and endothelial cells. Thus, melanoma-derived bFGF has potential paracrine functions in angiogenesis and stroma formation, although the mechanisms that determine its release by melanoma cells are not clear. Many chaperone molecules have been postulated to promote release of bFGF from cells, such as soluble FGF receptor (Seno et al., 1998) , FGF binding protein (Czubayko et al., 1997) and a Na + K + -ATPase (Florkiewicz et al., 1998) . Because melanoma cells produce a variety of growth factors with overlapping activities, it has been dicult to delineate precisely the functions for bFGF in these cells. To analyse both autocrine and paracrine mechanisms of bFGF in the melanocytic cell system, we transduced normal melanocytes, which represent the pre-tumorigenic phenotype and do not express bFGF, with recombinant adenoviral vectors (Satyamoorthy et al., 1996) . The viral vectors carry two cDNAs which independently encode the 17.8 kDa form of bFGF protein only or the 17.8 kDa form plus three larger forms Prats et al., 1992) . The episomal nature of adenoviral replication (Nelson and Kay, 1997) makes these vectors uniquely suited for transient but highly ecient expression of growth factors. We ®nd that melanocytes transduced with either bFGF adenoviral construct require only phorbol ester to survive in culture, form colonies in soft agar, and proliferate when injected into human skin grafted to severe combined immunode®cient (SCID) mice. Our results demonstrate the profound eects of bFGF overexpression on human melanocytic cells, which leads to a transformed phenotype and emphasizes the central role of bFGF overexpression and secretion in the progression of melanocytes to melanoma.
Results

Induction of bFGF expression
Lysates from FM 2176 melanocyte cultures transduced with either bFGF-Short (S) or bFGF-Long (L) using adenoviral vectors contained the 17.8 kDa form of bFGF, although levels of the protein were much higher using the bFGF-S/Ad5 vector ( Figure 1a) . The higher molecular weight forms of bFGF (24.2 kDa, 23.1 kDa and 22.5 kDa) were synthesized only in cells transduced with bFGF-L. Whereas Western blotting revealed no release of bFGF from transduced cells into the supernatant, the more sensitive ELISA technique indicated bFGF release, particularly by bFGF-S-transduced cells (Figure 1b) . bFGF was released from melanocyte cultures medium with over 98% viability as determined by trypan blue exclusion, suggesting that bFGF release is not due to cell death. Melanocytes transduced with bFGF-S release after 72 h up to 50 pg bFGF per 5610 5 cells (Figure 1b ) which represents only a fraction of the 1 ± 2 mg total bFGF produced by 2610 5 transduced cells over the same time period. Melanoma cells in culture generally do not release bFGF (Becker et al., 1989) but we found one out of 16 cell lines which did (Figure 1c ). Melanocytes transduced with the two forms of bFGF also diered in bFGF localization, with bFGF-Stransduced cells showing uniform cytoplasmic staining, whereas bFGF-L/Ad5-transduced cells showed nuclear and cytoplasmic staining (Figure 2a,b) . Control virus treated-transduced or untreated cultures showed no bFGF staining (Figure 2c,d) . Normal human melanocytes require bFGF, insulin or insulin-like growth factor-1, TPA and a-MSH for proliferation in serum-free medium (Herlyn et al., 1988) . Melanocytes transduced with either bFGF-S/ Ad5 or bFGF-L/Ad5 grew independent of exogenous bFGF and also of insulin/insulin-like growth factor-1 and a-MSH (Figure 3a ). There were essentially no in vitro growth dierences between the bFGF-S and bFGF-L transduced cells. Melanocytes transduced /cm 2 and transduced with bFGF-S, bFGF-L, control lacZ cDNA or mock (PBS alone) using adenoviral vectors at 20 p.f.u./cell. Cells were maintained in chemically de®ned W489 medium with phorbol ester as the only supplement and duplicate cultures were counted on days 1, 4 and 9 with one medium change on day 4. Similar results were obtained with cultures FM2126 and FM2176. Error bars indicate mean of standard deviation. (b) Anchorageindependent growth in soft agar was tested for melanocyte cell lines. First, 35-mm wells were coated with 0.5% agar in 1 ml melanocyte growth medium. Second, 3610 4 melanocytes of three cultures, transduced 24 h before with either bFGF-S, bFGF-L, LacZ or not transduced, were resuspended in 0.3% agar in melanocyte growth medium. The cultures were fed after 5 days with medium and colonies of four or more cells were counted 10 days after seeding. Colonies were counted in ®ve randomly selected ®elds at 206magni®cation. Results are expressed as per cent colony formation with the mean of standard deviation. Corresponding examples of single cells (control groups) or colonies (bFGF-transduced cells) are given on the right with either bFGF-S or bFGF-L formed colonies in soft agar at up to 5% colony-forming eciency, which is similar to that of primary melanomas from the vertical growth phase (Hsu et al., 1999) . On the other hand cells transduced with the control vector or not transduced formed no colonies ( Figure 3b ).
In order to determine the in vivo growth characteristic of bFGF expressing melanocytes, cells of three human melanocyte cultures, FM2201, FM2126 and FM2176, transduced with bFGF-S, bFGF-L or control lacZ, were injected intradermally into human skin grafted to SCID mice and tested for survival and growth. After 6 days, human skin xenografts injected with bFGF-transduced melanocytes showed numerous cells staining for the melanocyte marker S-100 ( Figure  4a ). Positive cells were distributed throughout the injected area in the skin with numerous stromal cells surrounding. No dierences were found among the three melanocyte strains transduced with either bFGF-S or bFGF-L. After 6 days, human skin injected with bFGF-S-or bFGF-L-transduced melanocytes contained numerous proliferating cells (melanocytes and
Growth of bFGF-transduced normal melanocytes in human skin grafted to SCID mice. Transduced FM2201 melanocytes were injected at 1610 7 cells/100 ml intradermally into the xenografts. All arrows indicate positively staining cells. (a) bFGF-Ltransduced melanocytes in human skin at 6 days; cells are stained with anti-S100 mAb; a marker for melanoma. (b) Same specimen stained with mAb detecting the human nuclear proliferation marker Ki67. (c) LacZ-transduced melanocytes stained for S100 expression at 6 days. (d) LacZ-transduced melanocytes stained for Ki67 at 6 days. (e) Normal skin xenotransplant stained with anti-S100 mAb, showing staining of melanocytes at the epidermal-dermal junction but not in the dermis stromal cells), as indicated by the expression of the proliferation marker Ki67 (Figure 4b ), whereas skin injected with control vector-transduced cells showed no Ki67 expression (not shown). Melanocytes transduced with control lacZ showed reduced survival after 6 days and the injection area in the dermis contained few stromal cells (Figure 4c ). LacZ transduced melanocytes injected into human skin showed Ki67 expression in the epidermis only (Figure 4d ). Melanocytes normally residing in the skin were restricted to the basal layer between the epidermis and dermis (Figure 4e ). There was little cellularity in untreated human dermis.
Discussion bFGF is an essential mitogen for melanocytes, but not for melanoma cells, which synthesize this protein for autocrine growth stimulation (Herlyn and Shih, 1994 ). Our results demonstrate that upregulation of bFGF in normal human melanocytes induces a transformed phenotype. Independence from exogenous bFGF for melanocyte proliferation in vitro is one of the characteristics associated with transformation. In the human melanocyte system, only cells from primary and metastatic melanomas grow in the absence of exogenous bFGF (Rodeck et al., 1987; Satyamoorthy et al., 1997) . Some but not all benign nevus cell lines also proliferate without bFGF due to autoproduction (Mancianti et al., 1993) . Dotto et al. (1989) have reported independence from bFGF for murine melanocytes transduced with the bFGF gene, whereas Coleman and Lugo (1998) found that human melanocytes transduced with bFGF in a retroviral vector continued their dependence on exogenous bFGF. The discrepancy between our ®ndings and those of Coleman and Lugo most likely rests in the higher quantity of bFGF induced in cells by the adenoviral versus the retroviral vector, although direct comparisons have not been made.
We also observed anchorage-independent growth in soft agar, another transformation-associated property. Normal melanocytes are unable to grow anchorage independently (Herlyn et al., 1985) and nevus cells form colonies at 1 ± 3% eciencies at the very most (Mancianti et al., 1993) . Primary melanoma cells, on the other hand, reach eciencies of 5% (Herlyn et al., 1985; Hsu et al., 1999) , comparable to our observation with bFGF-transduced melanocytes. Growth in soft agar resulted in loss of dendritic morphology yet the cells retained pigment unlike previous experiments where transformed murine melanocytes lost pigmentation (Dotto et al., 1989) . We also show that only one human melanoma cell line secreted any measurable bFGF and whereas all contained bFGF as determined by Western blotting (data not shown). The transduced melanocytes also survived and proliferated in human dermis. Proliferation of melanocytes normally depends on their close proximity to keratinocytes, which provide growth factors but which also regulate their growth (ValyiNagy et al., 1993) . Even radial growth phase primary melanoma cells cannot survive outside the epidermal environment (Hsu et al., 1998) . At 3 weeks, bFGFtransduced melanocytes continued to be present in the skin, whereas most cells transduced with the control vector had already died after 6 days. Because of the episomal nature of the adenoviral vectors used for gene transfer, we did not extend the observation beyond the 3 weeks.
bFGF-transduced melanocytes grew independently of insulin or IGF-1 (which both act through the IGF-1 receptor), bFGF and aMSH. The overproduction of bFGF by the transduced cells is apparently sucient to activate signaling pathways induced by insulin or IGF-1 and aMSH. Melanocytes require cAMP enhancers such as a-MSH, forskolin, or choleratoxin for growth in culture under chemically de®ned conditions (AbdelMalek et al., 1992; Herlyn et al., 1988) . bFGF also appears to activate the protein kinase A (PKA) pathway and enhances levels of cyclic adenosine 3', 5' monophosphate (cAMP) (deOliveira et al., 1996) . The binding of aMSH to high anity receptors on melanocytes and subsequent progression through S phase is dependent on bFGF (De Luca et al., 1993) .
bFGF can enhance intracellular PKC activity (deOliveira et al., 1996) by interacting with the FGFR-1 receptor (Becker et al., 1992) , and at present it is unclear why phorbol ester is still required and which particular isoforms of FGFR-1 are present in melanocytes. Activation of PKC was previously implicated in the mitogenesis of melanocytes when the speci®c PKC inhibitor calphostin c was found to abrogate the TPA response (Nakazawa et al., 1996) . The persistent activation of PKC by phorbol ester may represent a quantitative dierence in the requirement of PKC activation of human melanocytes.
Cells transduced with the adenoviral vectors inducing the mature 17.8 kDa form (bFGF-S) or the 17.8, 22.5, 23.1 and 24.2 kDa forms (bFGF-L) diered in the distribution of bFGF produced; bFGF-L-transduced melanocytes contained bFGF in both the cytoplasm and nucleus, whereas bFGF-S induced only cytoplasmic bFGF. The nuclear localization of bFGF has been attributed to a nuclear localization sequence present only in the alternatively translated forms of bFGF expressing the 24.2, 23.1 and 22.5 kDa isoforms . The transformed phenotype of NIH3T3 cells was shown to correlate with dierent bFGF isoforms (Quarto et al., 1989) , commensurate with the level of expression (Quarto et al., 1991) . The translation of bFGF might be modi®ed at the transcriptional level by cis-acting factors that function in a cell-speci®c manner and in relation to the structure of the bFGF mRNA (Prats et al., 1992) . The role of bFGF localized in the nucleus remains unclear, but it has been variously suggested to potentiate transcription of rRNA or entry through S phase of the cell cycle by its accumulation in G1 (Baldin et al., 1990) or to determine resistance of cells to radiation (CohenJonathan et al., 1997) . Studies of bacterially derived 18 and 24 kDa bFGF isoforms suggested no inherent biological dierences between these two forms with regard to mitogenicity, although the two species localized dierentially within the cells (Gualandris et al., 1994) . Similarly, we detected no real dierences in the biological activities of bFGF-S-or bFGF-Ltransduced cells with respect to growth in monolayer and in soft agar and also in survival and growth in vivo, despite the much higher production levels by bFGF-S. Thus, the nuclear localization induced by bFGF-L may have biological consequences that compensate for the reduced production levels.
Both vectors induced release of bFGF into the cell culture supernatant, albeit at low levels. Because bFGF released by cells in vivo is mainly bound by heparan sulfate proteoglycan in the extracellular matrix, low levels of soluble growth factor in the culture supernatant might also involve a binding protein. We also show that only a small fraction of the total bFGF is secreted and present in culture supernatant. The low levels of bFGF in culture supernatant are either due to ineciency of the secretory process or rapid binding to bFGF binding proteins such as proteoglycans on the cell surface. The exuberant stimulation of stromal cells after injecting bFGF-expressing melanocytes into human skin engrafted to mice strongly suggests the release of growth factor by cells. This release appears to be an active process and not due to cell death, because after 6 days, the injected melanocytes were viable and proliferating with no apparent cell death. In culture transduced melanocytes remained viable, suggesting similar mechanisms both in vitro and in vivo. Thus, bFGF may have considerable paracrine eects in vivo for stimulation of stroma formation of tumors. The quantitative increase in bFGF production with tumor progression, as observed in melanomas in vitro and in vivo, has important consequences for tumor growth, invasion and metastasis, underscoring the promise of bFGF as a target for therapy.
Materials and methods
Cell lines
Normal human melanocytes were obtained from newborn foreskins as described (Horikawa et al., 1996) . They were cultured in MCDB 153 (Sigma, St Louis, MO, USA) with 20% L15 (Sigma), supplemented with 2 mM CaCl 2 , 2% fetal calf serum (FCS) (Irvine Scienti®c, Irvine, CA, USA) and 5 mg/ml insulin (Sigma), 10 ng/ml epidermal growth factor (EGF), 140 mg/ml bovine pituitary extract (BPE) and 10 ng/ ml 12-O-tetradecanoyl phorbol-13-acetate (TPA). Human melanoma cells were maintained in MCDB 153 medium with 20% L15 media supplemented with 2 mM CaCl 2 , 2% FCS and 5 mg/ml insulin.
Adenovirus construction
To account for potential dierences in the release and cellular location of dierent isoforms of bFGF by melanoma cells, two vectors were constructed. Neither vector had a signal peptide sequence inserted. bFGF-L (Long) encodes an alternatively translated region (ATR), giving rise to proteins of 24.2, 23.1 and 22.5 kDa translated from CUG initiating codons, which are 5' and in-frame to the endogenous AUG codon. This construct also yields the 17.8 kDa mature form of bFGF. The second adenoviral construct does not encode the alternate CUG codons, because the ATR is not present and translation is directed from the endogenous AUG codon, giving rise to the 17.8 kDa mature form of bFGF only [bFGF-S (Short)]. Two plasmids containing the human bFGF cDNAs (kindly provided by Dr Anne Hanneken, Scripps Research Institute, La Jolla, CA, USA), were used in producing bFGF adenoviral constructs. One plasmid (18DX) containing the *700 bp cDNA that encodes the 17.8 kDa form of wild-type bFGF was used to construct the adenoviral vector bFGF-S/Ad5. The other plasmid (P363) containing the *1050 bp cDNA that encodes the 24.2, 23.1 and 22.5 kDa forms of bFGF as well as the 17.8 kDa form was used to produce the adenoviral vector bFGF-L/Ad5. 18DX and P363 were subcloned into pAdCMV-Link.1 vector (obtained from the Vector Core, Institute Human Gene Therapy, University of Pennsylvania, Philadelphia, PA, USA), under the control of the cytomegalovirus (CMV) intermediate/early enhancer-promoter element and SV40 polyadenylation signal; the plasmid contains adenovirus 5 genomic sequences encoding map units 0 ± 1 and 9 ± 16. 18DX was excised with XhoI; pAdCMV-Link.1 was linearized with BglII at the multiple cloning site and ligated after a two-base ®ll-in reaction. P363 was excised with EcoRI; pAdCMV-Link.1 was linearized with EcoRV, P363 was blunt-ended by a four-base ®ll-in reaction and ligated into pAdCMV-Link.1 (Weitzman et al., 1995) . Correct orientation of the insert was determined by restriction analysis and sequencing. Adenovirus vectors were prepared, puri®ed and titered to 10 11 plaque-forming units (p.f.u.)/ml as described (Kozarsky and Wilson, 1993) . The adenoviral vector LacZ/Ad5 expressing the b-galactosidase enzyme from E. coli (Vector Core, Institute of Human Gene Therapy, University of Pennsylvania Philadelphia, PA, USA) was used as a viral control.
Monoclonal antibody (mAb) production bFGF was produced from E. coli as a GST fusion protein and anity-puri®ed on glutathione-sepharose beads (Pharmacia Biotech, Piscataway, NJ, USA). The cDNA was cloned into the PGEX-2T vector and recombinant protein induced, puri®ed and cleaved with thrombin according to the manufacturer's instructions (Pharmacia Biotech). An 18 kDa protein was shown to be the major band upon SDS ± PAGE. Western analysis indicated reactivity of this protein with rabbit polyclonal antibody speci®c for bFGF (Ab-2; Oncogene Research Products, Cambridge, MA, USA). Balb/c mice were immunized s.c. with 50 mg of recombinant protein in complete Freund's adjuvant, followed by three injections of bFGF in Freund's incomplete adjuvant at 2 weekly intervals. Three days prior to fusion, 50 mg of bFGF was given i.v. without adjuvant. Murine myeloma cells SP/20 were used for fusion and two hybridomas (bFGF-8 and bFGF-11, both IgG1, k) were selected for speci®c binding to recombinant bFGF in enzyme-linked immunosorbent assays (ELISA). Western blotting con®rmed bFGF binding of the mAb.
Cell proliferation assay
Melanocytes were grown for 1 week before transduction in chemically de®ned melanocyte media consisting of MCDB 153 with 20% L15 and supplemented with 5 mg/ml insulin, 1 ng/ml bFGF, 10 76 M a-melanocyte-stimulating hormone (MSH) and 10 76 M 20-oxo-phorbol-12,13-dibutyrate (PDBu). Melanocytes were then transduced with the adenoviral constructs in duplicate wells at 1610 4 cells/cm 2 in 6-well plates for 2 h in protein-free media (MCDB 153 with 20% L15 only) at 20 p.f.u./cell. Cells were maintained for 1 day in the protein-free medium, which was then supplemented with PDBu, and duplicate samples were counted on days 1, 4 and 9 to determine number of viable cells.
For anchorage-independent growth in soft agar, 3610 4 cells were resuspended in a ®nal volume of 2 ml containing 0.3% agar Noble agar (DIFCO, Detroit, MI, USA) in melanocyte growth medium. Cells were added to 6-well plates (Falcon; Becton Dickinson Labware, Lincoln Park, NJ, USA) containing 1 ml/well of 0.5% agar in melanocyte growth medium. After 5 days, new growth medium in agar Transformation of human melanocytes by bFGF M Nesbit et al was added and 5 days later, colonies of four or more cells/ colony were counted in ®ve random ®elds.
Protein detection
For Western blot analyses, transduced melanocytes were grown in growth medium for 24 h and in protein-free medium supplemented only with PDBu for 72 h. Samples equivalent to 2610 5 cells in Laemmli loading buer or supernatant from transduced cells in the same buer were separated overnight on a 15% SDS ± polyacrylamide gel at 35 V and then transferred overnight at 35 V to PVDF membranes (Millipore Corp, Bedford, MA, USA). Membranes were blocked for 1 h at room temperature with 1% BSA (Sigma). Blots were rinsed and probed with mAb bFGF-8, washed extensively and probed with goat antimouse IgG linked to phosphatase (Jackson ImmunoResearch Laboratories Inc, West Grove, PA, USA) for 1 h. After extensive washing, blots were developed using the NBT and BCIP chromagen system (Sigma). bFGF levels in culture supernatants were quantitated using a bFGF ELISA according to the manufacturer's instructions (R&D Systems).
For intracellular staining of bFGF, transduced melanocytes on coverslips were ®xed in 3% paraformaldehyde followed by methanol treatment at 7208C to permeabilize the cells. Fixed cells were blocked with 10% FCS in phosfatebuered saline (PBS) and incubated with rabbit polyclonal antiserum against bFGF (Oncogene Science), mAb bFGF-8 or bFGF-11 or normal rabbit or mouse IgG in 10% FCS for 2 h at room temperature. After three washes, cells were incubated with anti-rabbit or anti-mouse IgG linked tō uorescein isothiocyanate and evaluated.
Human skin grafts
Human neonatal foreskin was grafted to CB.17 SCID mice as described Yan et al., 1993) . After 6 weeks, when the grafts had healed, 3610 6 melanocytes in 100 ml growth medium were injected intradermally. Skin grafts were harvested 6, 14 and 20 days later for histological and immunohistological evaluation. Serial 5 mm paran sections were stained with hematoxylin and eosin for histological analyses. Sections of OCT-embedded and frozen tissues were stained with mAb using an avidinbiotin-peroxidase kit (Vector Lab, Burlingame, CA, USA). Brie¯y, sections were acetone-®xed for 10 min at 48C, incubated overnight at 48C with mAb in a humidi®ed chamber, rinsed and further incubated with biotinylated antimouse IgG for 30 min at room temperature, followed by avidin-biotin-peroxidase complex for 45 min. Slides were rinsed, developed with 3,3'-diaminobenzidine and counterstained with hematoxylin.
